Current treatment options and biology of peritoneal mesothelioma: Meeting summary of the first NIH peritoneal mesothelioma conference Journal Article
| Authors: | Hassan, R.; Alexander, R.; Antman, K.; Boffetta, P.; Churg, A.; Coit, D.; Hausner, P.; Kennedy, R.; Kindler, H.; Metintas, M.; Mutti, L.; Onda, M.; Pass, H.; Premkumar, A.; Roggli, V.; Sterman, D.; Sugarbaker, P.; Taub, R.; Verschraegen, C. |
| Article Title: | Current treatment options and biology of peritoneal mesothelioma: Meeting summary of the first NIH peritoneal mesothelioma conference |
| Abstract: | Peritoneal mesothelioma is a rare cancer of the peritoneum with about 250 new cases diagnosed each year in the United States. It is the second most common site for mesothelioma development and accounts for 10-20% of all mesotheliomas diagnosed in the United States. A meeting sponsored by the NIH Office of Rare Diseases was held in Bethesda, Maryland on September 13 and 14, 2004. The objective of this meeting was to review the epidemiology, biology and current surgical and medical management of peritoneal mesothelioma. In addition, the meeting also discussed clinical and pre-clinical evaluation of novel treatments for mesothelioma as well as ongoing laboratory research to better understand this disease. This report summarizes the proceedings of the meeting as well as directions for future clinical and basic research. © 2006 Oxford University Press. |
| Keywords: | cancer survival; surgical technique; overall survival; thalidomide; clinical trial; disease course; review; bevacizumab; cisplatin; doxorubicin; fluorouracil; placebo; united states; gemcitabine; paclitaxel; cancer radiotherapy; nuclear magnetic resonance imaging; positron emission tomography; cancer incidence; laparotomy; genetic analysis; cytoreductive surgery; medical decision making; electron microscopy; imatinib; unindexed drug; quality of life; bortezomib; computer assisted tomography; peritoneal neoplasms; differential diagnosis; carcinoembryonic antigen; patient monitoring; drug evaluation, preclinical; proteomics; tumor antigen; cancer research; carcinogenesis; monoclonal antibody; lung metastasis; drug research; gamma interferon; early diagnosis; contrast enhancement; gefitinib; semaxanib; malignant mesothelioma; pleura mesothelioma; mesothelioma; simian virus 40; tumor immunity; contrast medium; turkey (republic); thymidine kinase; adenovirus vector; abdominal surgery; cytokeratin 5; cytokeratin 6; health care organization; pemetrexed; herpes simplex virus; beta interferon; environmental exposure; peritoneum mesothelioma; clinical trials; national institutes of health (u.s.); calretinin; mesothelin; thrombomodulin; phosphatidylinositol 3 kinase inhibitor; occupational exposure; asbestos; immunotoxin; peritoneal; thorium dioxide; epidemiological data |
| Journal Title: | Annals of Oncology |
| Volume: | 17 |
| Issue: | 11 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2006-11-01 |
| Start Page: | 1615 |
| End Page: | 1619 |
| Language: | English |
| DOI: | 10.1093/annonc/mdl060 |
| PUBMED: | 16600983 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 12" - "Export Date: 4 June 2012" - "CODEN: ANONE" - "Source: Scopus" |
